PUBLICATIONS - New from Clinica Reports - Biochips and Microarrays
This article was originally published in Clinica
Executive Summary
Executive Summary The world of biochips and microarrays is a world of laboratories in miniature. Given the technology, it makes sense to shrink the laboratory onto a small glass or nylon slide. Most of the biological reactions we need to examine occur at the sub-cellular level and to confront them at that scale offers practical advantages - including speed and the ability to condense a whole battery of assays or tests into a space measuring just a few millimetres square. Indeed, now that we are receiving the structure of the whole human genome, there is a pressing need for miniaturisation of test systems. To convert the mass of data thus revealed into tests of practical use would be extremely clumsy if we were still relying on laboratory procedures of 'conventional' scale.
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.